Novartis touts mid-stage results for MenB

Novartis says that a mid-stage study of its MenB vaccine demonstrated broad protection from meningococcal B infections in infants. Researchers tracked positive results starting with three immunizations starting at an age of two months. If the vaccine ultimately proves successful in gaining regulatory approval, it will be the first broad coverage vaccine intended to protect infants from meningococcal B strain, which is responsible for 72 percent of meningococcal disease in Europe. Novartis released the data at the European Society for Paediatric Infectious Diseases meeting and says that a vaccine could be on the market in three years.

"The prospect of one vaccine that protects infants worldwide against meningococcal serogroup B would be a key achievement in global disease prevention of our time," said Ray Borrow, PhD, head of the vaccine evaluation unit of the UK's Health Protection Agency. "Of those infected with the meningococcal B strain, there is a strong likelihood that the bacterium contains at least one of the antigens included in the Novartis MenB vaccine. These new findings tell us that the vaccine is likely to kill strains that contain the vaccine's antigens."

 

- check out the Novartis release
- read the story in the Telegraph
-
here's the report from Hemscott

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.